Latuda vs Rexulti
Side-by-side cost comparison based on Medicare Part D data
Latuda
Lurasidone
Manufactured by Sunovion
Rexulti
Brexpiprazole
Manufactured by Otsuka
Latuda costs 24% less per claim than Rexulti ($300.00 vs $396.00). A generic version of Latuda is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Latuda | Rexulti |
|---|---|---|
| Avg Cost Per Claim | $300.00 | $396.00 |
| Total Medicare Spending | $1.4B | $1.2B |
| Total Beneficiaries | 512,000 | 356,000 |
| Total Claims | 4,560,000 | 3,120,000 |
| Annual Cost/Patient | $2,670.00 | $3,466.00 |
| Year-over-Year Change | -32.5% | +22.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Feb 19, 2023 | Jan 31, 2023 |
| Manufacturer | Sunovion | Otsuka |
| Condition | Mental Health | Mental Health |
| Generic Name | Lurasidone | Brexpiprazole |
Latuda vs Rexulti: What the Data Shows
Latuda (Lurasidone) and Rexulti (Brexpiprazole) are both used to treat mental health. Based on Medicare Part D data, Latuda costs $300.00 per claim, which is 24% less than Rexulti at $396.00 per claim.
Medicare spent $1.4B on Latuda and $1.2B on Rexulti. In terms of patient reach, Latuda serves more beneficiaries (512,000 vs 356,000).
Year-over-year spending changed -32.5% for Latuda and +22.4% for Rexulti. Rexulti saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Latuda is cheaper at $300.00 per claim, compared to $396.00 for Rexulti. That makes Latuda about 24% less expensive per claim based on Medicare Part D data.
Yes, both Latuda and Rexulti are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Lurasidone and generic Brexpiprazole can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.4B on Latuda covering 512,000 beneficiaries, and $1.2B on Rexulti covering 356,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.